Covid-19 roundup: An old, cheap steroid proves to be a ma­jor boon to coro­n­avirus pa­tients; BAR­DA puts $85M be­hind ...

6 years ago
Coronavirus

Bil­lions on the ta­ble, GSK’s Hal Bar­ron antes $120M cash to part­ner with a spe­cial­ist in syn­thet­ic lethal­i­ty

6 years ago
Deals

Eye­ing a hot IPO mar­ket, 4DMT tops up its cash re­serves and preps a leap in­to the clin­ic with be­spoke gene ther­a­py ...

6 years ago
Financing
Cell/Gene Tx

Jazz Phar­ma’s $1B bet pays off with ac­cel­er­at­ed lung can­cer ap­proval

6 years ago
R&D
FDA+

It's not just Charles Lieber: NI­H's on­go­ing in­ves­ti­ga­tion has swept up 54 sci­en­tists who vi­o­lat­ed rules about for­eign ...

6 years ago
China

The FDA backs off a hasty — and dam­ag­ing — emer­gency OK for a po­ten­tial­ly dan­ger­ous Covid-19 drug

6 years ago
Bioregnum
R&D

Shat­tuck Labs ends si­lence with a shout-out on $118M raise for fu­sion pro­tein work

6 years ago
Financing
Startups

SK Bio­phar­ma­ceu­ti­cals emerges from pan­dem­ic with pitch for $822M IPO

6 years ago
Financing

With Sanofi en­ter­ing the mul­ti­ple myelo­ma mar­ket, J&J flash­es da­ta on new rare dis­ease

6 years ago
R&D

On a hir­ing spree, Mod­er­na re­cruits an­oth­er Am­gen vet for the ex­ec­u­tive com­mit­tee; Re­pare, For­ma set terms for IPO

6 years ago
News Briefing

A pi­o­neer­ing im­muno-on­col­o­gy re­searcher heads back to Dana-Far­ber as Eli Lil­ly’s can­cer R&D group un­der­goes a ...

6 years ago
People
R&D

Covid-19 roundup: Catal­ent lends vac­cine pro­duc­tion ca­pac­i­ty to As­traZeneca/Ox­ford for hun­dreds of mil­lions dos­es

6 years ago
Financing
Coronavirus

Eli Lil­ly launch­es PhI­II JAK study, aim­ing for the first drug to low­er mor­tal­i­ty in Covid-19

6 years ago
R&D
Coronavirus

Mo­men­ta clears a PhII hur­dle on nipo — but one big ri­val re­mains well in the lead in this packed field

6 years ago
R&D

Sure, Bit Bio got some sig­nif­i­cant cash for its cell cod­ing work. But it’s the in­sid­ers who are back­ing them that ...

6 years ago
Financing
R&D

Sino­vac posts pos­i­tive PhI/II da­ta for their Covid-19 vac­cine as re­searchers rush in­to a piv­otal test

6 years ago
R&D
Coronavirus

UCB flash­es the da­ta be­hind its pos­i­tive pso­ri­a­sis read­outs. Can it com­pete in a crowd­ed field?

6 years ago
R&D

'Ris­ing star' CEO re­counts path from pre-med to break­through meds; Den­dreon taps Big Phar­ma vet Ja­son O'Neill as CEO

6 years ago
Peer Review

Sanofi and Re­gen­eron out­line Dupix­ent plans; In­dus­try lob­by­ing brings £30 mil­lion for UK's Bio­med­ical Cat­a­lyst

6 years ago
News Briefing

Can­cer drug­mak­er Agios of­fers promis­ing da­ta from two stud­ies test­ing blood dis­or­der drug

6 years ago
Deals
R&D

The pan­dem­ic IPOs keep rolling, as Gen­er­a­tion, Avid­i­ty, Vax­cyte each claim 200M+

6 years ago
Financing

Mod­er­na bur­nish­es its PhI­II-ready Covid-19 vac­cine with promis­ing mouse da­ta — which sug­gest one dose might be ...

6 years ago
R&D
Coronavirus

Covid-19 roundup: Chi­na's Sino­vac goes to Brazil for PhI­II; As­traZeneca signs Emer­gent on for $87M man­u­fac­tur­ing deal

6 years ago
Coronavirus

FDA weighs post-pan­dem­ic chal­lenges at BIO meet­ing

6 years ago
FDA+
Coronavirus
First page Previous page 832833834835836837838 Next page Last page
A service from the Financial Times